Clinical Data:

• Nerivio (REN) provides an efficacious and safe treatment option for acute treatment of migraine in real-world settings, with pain relief and pain freedom achieved in over 66% and 22% of patients, respectively, and device-related adverse events reported in only 0.48% of users.
• REN may have higher efficacy than certain standard-care medications for the acute treatment of migraine in adolescents, with pain freedom achieved in over 37% of patients compared to 8.6% of patients with medications.
• REN may reduce the use of acute migraine medications, with nearly 90% of patients treated only with REN and avoiding medications in all attacks, compared with only 15.4% who avoided medications before REN was introduced.

Mechanism:

• Uses neuromodulation technology to provide non-invasive treatment for migraine headaches.
• The app delivers a mild electrical stimulation to the upper arm, which stimulates the body's pain-fighting mechanisms and reduces theintensity of migraine pain.

Safety and Side Effects:

• The most commonly reported side effects include skin irritation at the site of stimulation and discomfort during the treatment session.

Patient Eligibility:

• Nerivio is intended for use by individuals who suffer from migraines.
• The app is not recommended for individuals with implanted medical devices, such as pacemakers or defibrillators.

Cost:

• Nerivio is available by prescription only and may be covered by insurance.